 |
50 Diseases |  |
29 Trials |
|
29 Trials |  |
3299 News |  |
| «12...27282930313233343536373839» |
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: NIMRA: Novel Imaging Markers for Rheumatoid Arthritis (clinicaltrials.gov) - Nov 30, 2018
P=N/A, N=30, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed
- | New P4 trial: Dose reduction and withdrawal of TNF inhibitors in patients with Psoriatic Arthritis and Axial Spondyloarthritis Afbouwen en stoppen van TNF remmers bij pati (EUDRACT) - Nov 23, 2018
P4, N=234, Ongoing, Sponsor: Sint Maartenskliniek
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CIMPASI-2: A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Oct 17, 2018
P3, N=227, Completed, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: National Data Bank for Rheumatic Disease Registry Study of Safety in Patients With Rheumatoid Arthritis Treated With Cimzia (clinicaltrials.gov) - Oct 16, 2018
P=N/A, N=12500, Enrolling by invitation, Sponsor: UCB Pharma
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Dec 2018
- | Trial completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Oct 12, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
Trial completion date: Apr 2018 --> Dec 2018 Trial completion date: Jun 2018 --> Dec 2018
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open, Trial initiation date: Zr-89 Cimzia PET Imaging Rheumatoid Arthritis (clinicaltrials.gov) - Oct 11, 2018
P1, N=10, Recruiting, Sponsor: University of California, San Francisco
Trial completion date: Jun 2018 --> Dec 2018 Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Oct 2018
- | Biomarker, Trial completion date, Trial primary completion date: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Aug 21, 2018
P4, N=110, Recruiting, Sponsor: Medical University of Graz
Not yet recruiting --> Recruiting | Initiation date: Jun 2018 --> Oct 2018 Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Clinical, Journal: Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment. (Pubmed Central) - Aug 8, 2018
P3
Predicted SIE risk was not associated with patients' likelihood of clinical response. This SIE risk score may provide a valuable tool for clinicians when considering the risk of infection in individual patients with RA.
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Trial completion date, Trial primary completion date: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Aug 3, 2018
P4, N=90, Recruiting, Sponsor: Dr. Larry W. Moreland
This SIE risk score may provide a valuable tool for clinicians when considering the risk of infection in individual patients with RA. Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion, Trial completion date: RICE: Remission by Intra-articular Injection Plus CErtolizumab (clinicaltrials.gov) - Aug 3, 2018
P2, N=43, Completed, Sponsor: R
Trial completion date: Jul 2018 --> Jul 2019 | Trial primary completion date: Jul 2018 --> Jul 2019 Recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018
- | Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: SWIFT: A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 1, 2018
P3b, N=3, Terminated, Sponsor: UCB Pharma
Recruiting --> Completed | Trial completion date: Jul 2018 --> Jan 2018 Phase classification: P3 --> P3b
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jul 27, 2018
P3, N=70, Completed, Sponsor: UCB Biopharma S.P.R.L.
Phase classification: P3 --> P3b Active, not recruiting --> Completed
- | Clinical, Review, Journal: Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - Jul 25, 2018
Active, not recruiting --> Completed Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications.
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P1 trial: Zr-89 Cimzia PET Imaging Rheumatoid Arthritis (clinicaltrials.gov) - Jul 15, 2018
P1, N=10, Not yet recruiting, Sponsor: University of California, San Francisco
Infliximab and adalimumab have demonstrated efficacy in psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn's disease; other agents have demonstrated efficacy for some, but not all, of these indications. .
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Jun 29, 2018
P=N/A, N=1723, Active, not recruiting, Sponsor: UCB Pharma SA
. Recruiting --> Active, not recruiting
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Jun 19, 2018
P3, N=70, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Cimzia (certolizumab pegol) / Astellas, UCB
Trial termination, Trial primary completion date: UCB Cimzia Pregnancy Follow-up Study (clinicaltrials.gov) - Jun 11, 2018
P=N/A, N=360, Terminated, Sponsor: UCB BIOSCIENCES, Inc.
Recruiting --> Active, not recruiting Recruiting --> Terminated | Trial primary completion date: May 2027 --> Dec 2017
- | Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma, Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: NORD-STAR: Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction (clinicaltrials.gov) - Jun 4, 2018
P4, N=800, Recruiting, Sponsor: Karolinska Institutet
Recruiting --> Terminated | Trial primary completion date: May 2027 --> Dec 2017 Trial primary completion date: Mar 2019 --> Jun 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - Jun 1, 2018
P1, N=30, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Mar 2019 --> Jun 2019 Recruiting --> Active, not recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas (clinicaltrials.gov) - May 2, 2018
P1, N=34, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Study of Cimzia for the Treatment of Ulcerative Colitis (clinicaltrials.gov) - May 1, 2018
P2, N=25, Active, not recruiting, Sponsor: University of Washington
Trial completion date: Apr 2018 --> Apr 2019 | Trial primary completion date: Apr 2018 --> Apr 2019 Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Clinical, Journal: Temporal Trends in Use of Biologic DMARDs for Rheumatoid Arthritis in the United States: A Cohort Study of Publicly and Privately Insured Patients. (Pubmed Central) - Apr 18, 2018
Trial completion date: Dec 2017 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Dec 2018 More RA patients used bDMARDs in recent years, and use of newer agents, including certolizumab, golumumab, and tocilizuamab, is rising, which highlights a need for further comparative safety and effectiveness research of these agents to better guide evidence-based decision making.
- | New trial: Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs (clinicaltrials.gov) - Apr 17, 2018
P=N/A, N=7500, Completed, Sponsor: Simon Krabbe
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Combination therapy: A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-na (clinicaltrials.gov) - Apr 10, 2018
P3, N=359, Completed, Sponsor: UCB Pharma
More RA patients used bDMARDs in recent years, and use of newer agents, including certolizumab, golumumab, and tocilizuamab, is rising, which highlights a need for further comparative safety and effectiveness research of these agents to better guide evidence-based decision making. N=880 --> 359
- || Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Apr 5, 2018
P2a, N=60, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
N=880 --> 359 Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Feb 2018 --> Sep 2018
- ||||||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: CIMAX: A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (clinicaltrials.gov) - Mar 30, 2018
P, N=680, Completed, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Mar 2019 --> Sep 2019 | Trial primary completion date: Feb 2018 --> Sep 2018 Active, not recruiting --> Completed
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Enrollment open: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Mar 29, 2018
P4, N=400, Recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Mar 26, 2018
P, N=1700, Recruiting, Sponsor: UCB Pharma SA
Not yet recruiting --> Recruiting Phase classification: P=N/A --> P
- || Cimzia (certolizumab pegol) / Astellas, UCB
Phase classification: CIMAX: A Study to Assess the Effectiveness of Certolizumab Pegol in Patients With Axial Spondyloarthritis in Daily Life (clinicaltrials.gov) - Mar 26, 2018
P, N=680, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Phase classification: P=N/A --> P Phase classification: P=N/A --> P
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis (clinicaltrials.gov) - Mar 22, 2018
P3, N=42, Completed, Sponsor: ICStudy, LLC
Phase classification: P=N/A --> P Active, not recruiting --> Completed
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial primary completion date: A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis (clinicaltrials.gov) - Mar 3, 2018
P2/3, N=149, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Nov 2018
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Trial completion date, Trial initiation date, Trial primary completion date: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Mar 3, 2018
P4, N=400, Not yet recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Trial primary completion date: Dec 2018 --> Nov 2018 Trial completion date: Sep 2021 --> Oct 2021 | Initiation date: Feb 2018 --> Mar 2018 | Trial primary completion date: Sep 2018 --> Oct 2018
- || Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: C-VIEW: A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (clinicaltrials.gov) - Mar 3, 2018
P4, N=89, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Sep 2021 --> Oct 2021 | Initiation date: Feb 2018 --> Mar 2018 | Trial primary completion date: Sep 2018 --> Oct 2018 Trial completion date: Apr 2020 --> Mar 2020 | Trial primary completion date: Feb 2020 --> Jan 2020
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date: CIMPACT: Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO) (clinicaltrials.gov) - Mar 3, 2018
P3, N=559, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial completion date: Apr 2020 --> Mar 2020 | Trial primary completion date: Feb 2020 --> Jan 2020 Trial completion date: Dec 2018 --> Dec 2018
- |||| Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion date, Trial primary completion date: Pediatric Arthritis Study of Certolizumab Pegol (clinicaltrials.gov) - Feb 6, 2018
P3, N=163, Active, not recruiting, Sponsor: UCB BIOSCIENCES GmbH
Trial completion date: Dec 2018 --> Dec 2018 Trial primary completion date: Mar 2018 --> Feb 2019 | Trial completion date: May 2018 --> May 2019
- ||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Trial initiation date: C-VIEW: A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU (clinicaltrials.gov) - Feb 6, 2018
P4, N=89, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
Trial primary completion date: Mar 2018 --> Feb 2019 | Trial completion date: May 2018 --> May 2019 Recruiting --> Active, not recruiting | Initiation date: Jan 2017 --> Dec 2016
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease (clinicaltrials.gov) - Feb 5, 2018
P=N/A, N=50, Active, not recruiting, Sponsor: University of Maryland
Recruiting --> Active, not recruiting | Initiation date: Jan 2017 --> Dec 2016 Recruiting --> Active, not recruiting | N=90 --> 50 | Trial primary completion date: Aug 2016 --> Jun 2018 | Trial completion date: Aug 2017 --> Jun 2018
- | Actemra IV (tocilizumab) / Roche, JW Pharma
Biomarker, Trial initiation date: RAFTING: Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation (clinicaltrials.gov) - Feb 5, 2018
P4, N=400, Not yet recruiting, Sponsor: Mario Negri Institute for Pharmacological Research
Recruiting --> Active, not recruiting | N=90 --> 50 | Trial primary completion date: Aug 2016 --> Jun 2018 | Trial completion date: Aug 2017 --> Jun 2018 Initiation date: Nov 2017 --> Feb 2018
- | Review, Journal: Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. (Pubmed Central) - Dec 25, 2017
Herein we will review the mechanisms of action of these drugs, their results in clinical trials, and guidelines for administration. Lastly, treatment recommendations from the European League Against Rheumatism (EULAR) and The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) will be discussed.
- | Cimzia (certolizumab pegol) / Astellas, UCB
Trial completion: Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol (clinicaltrials.gov) - Dec 21, 2017
P2, N=16, Completed, Sponsor: UCB Pharma
Lastly, treatment recommendations from the European League Against Rheumatism (EULAR) and The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) will be discussed. Active, not recruiting --> Completed
- | Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Cimzia (certolizumab pegol) / Astellas, UCB, Eli Lilly
Journal: Effect of Anti-TNF Agents on Postoperative Outcomes in Inflammatory Bowel Disease Patients: a Single Institution Experience. (Pubmed Central) - Nov 30, 2017
Active, not recruiting --> Completed The use of anti-TNF medications in inflammatory bowel disease patients within 2 months of intestinal surgery is not associated with an increased risk of 30-day postoperative complications.
- |||||||||| Cimzia (certolizumab pegol) / Astellas, UCB
New P3 trial: Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease (clinicaltrials.gov) - Nov 30, 2017
P3, N=60, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
- ||||| Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis (clinicaltrials.gov) - Nov 22, 2017
P2/3, N=149, Active, not recruiting, Sponsor: UCB Biopharma S.P.R.L.
The use of anti-TNF medications in inflammatory bowel disease patients within 2 months of intestinal surgery is not associated with an increased risk of 30-day postoperative complications. Recruiting --> Active, not recruiting
- |||| Bimzelx (bimekizumab) / UCB, Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment open: A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis (clinicaltrials.gov) - Oct 27, 2017
P2a, N=60, Recruiting, Sponsor: UCB Biopharma S.P.R.L.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Enrollment open, Checkpoint inhibition: TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) - Oct 20, 2017
P1, N=30, Recruiting, Sponsor: Institut Claudius Regaud
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed, Enrollment change, Trial primary completion date: SECURE, the Cimzia (clinicaltrials.gov) - Sep 29, 2017
P=N/A, N=3045, Active, not recruiting, Sponsor: UCB Pharma
Not yet recruiting --> Recruiting Enrolling by invitation --> Active, not recruiting | N=4000 --> 3045 | Trial primary completion date: Dec 2028 --> Aug 2025
- | New P1 trial, Checkpoint inhibition: TICIMEL: TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (clinicaltrials.gov) - Sep 26, 2017
P1, N=30, Not yet recruiting, Sponsor: Institut Claudius Regaud
- | Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment closed: Study of Cimzia for the Treatment of Ulcerative Colitis (clinicaltrials.gov) - Aug 22, 2017
P2, N=25, Active, not recruiting, Sponsor: University of Washington
Enrolling by invitation --> Active, not recruiting | N=4000 --> 3045 | Trial primary completion date: Dec 2028 --> Aug 2025 Recruiting --> Active, not recruiting
- || Cimzia (certolizumab pegol) / Astellas, UCB
Enrollment change, Trial primary completion date: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors (clinicaltrials.gov) - Aug 22, 2017
P=N/A, N=1700, Recruiting, Sponsor: UCB Pharma SA
Recruiting --> Active, not recruiting N=1360 --> 1700 | Trial primary completion date: Mar 2020 --> Oct 2020
- || Orencia (abatacept) / BMS, Actemra IV (tocilizumab) / Roche, JW Pharma
Trial primary completion date: MAZERATI: Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept (clinicaltrials.gov) - Aug 10, 2017
P4, N=90, Recruiting, Sponsor: Dr. Larry W. Moreland
N=1360 --> 1700 | Trial primary completion date: Mar 2020 --> Oct 2020 Trial primary completion date: Jul 2017 --> Jul 2018